Abstract
The microbiota is a complex ecosystem of microorganisms consisting of bacteria, viruses, protozoa, and fungi, living in different districts of the human body, such as the gastro-enteric tube, skin, mouth, respiratory system, and the vagina. Over 70% of the microbiota lives in the gastrointestinal tract in a mutually beneficial relationship with its host. The microbiota plays a major role in many metabolic functions, including modulation of glucose and lipid homeostasis, regulation of satiety, production of energy and vitamins. It exerts a role in the regulation of several biochemical and physiological mechanisms through the production of metabolites and substances. In addition, the microbiota has important anti-carcinogenetic and anti-inflammatory actions. There is growing evidence that any modification in the microbiota composition can lead to several diseases, including metabolic diseases, such as obesity and diabetes, and cardiovascular diseases. This is because alterations in the microbiota composition can cause insulin resistance, inflammation, vascular, and metabolic disorders. The causes of the microbiota alterations and the mechanisms by which microbiota modifications can act on the development of metabolic and cardiovascular diseases have been reported. Current and future preventive and therapeutic strategies to prevent these diseases by an adequate modulation of the microbiota have been also discussed.
Similar content being viewed by others
Abbreviations
- AMPK:
-
AMP-Activated protein kinase
- CVD:
-
Cardiovascular diseases
- FIAF:
-
Fasting-induced adipose factor
- FMI:
-
Fecal microbiota transplant
- GLP-1:
-
Glucagon-like peptide 1
- GLP-2:
-
Glucagon-like peptide-2
- HDL:
-
High-density lipoprotein
- HFD:
-
High-fat diet
- IR:
-
Insulin resistance
- LPL:
-
Lipoprotein lipase
- LPS:
-
Lipopolysaccharide
- MS:
-
Metabolic syndrome
- PYY:
-
Peptide YY
- RYGB:
-
Roux-en-Y bypass
- SCFAs:
-
Short-chain fatty acids
- T1D:
-
Type 1 diabetes
- T2D:
-
Type 2 diabetes
- TLR4:
-
Toll-like receptor 4
- TMAO:
-
Trimethylamine-N-oxide
- VLDL:
-
Very low-density lipoprotein
References
R. Sender, S. Fuchs, R. Milo, Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14, e1002533 (2016). https://doi.org/10.1371/journal.pbio.1002533
C. Palmer, E.M. Bik, D.B. DiGiulio, D.A. Relman, P.O. Brown, Development of the human infant intestinal microbiota. PLoS Biol. 5, 1556–1573 (2007). https://doi.org/10.1371/journal.pbio.0050177
A. Pingitore, E.S. Chambers, T. Hill, I.R. Maldonado, B. Liu, G. Bewick, D.J. Morrison, T. Preston, G.A. Wallis, C. Tedford, R. Castañera González, G.C. Huang, P. Choudhary, G. Frost, S.J. Persaud, The diet-derived short chain fatty acid propionate improves beta-cell function in humans and stimulates insulin secretion from human islets in vitro. Diabetes Obes. Metab. 19, 257–265 (2017). https://doi.org/10.1111/dom.12811
F. Bäckhed, J. Roswall, Y. Peng, Q. Feng, H. Jia, P. Kovatcheva-Datchary, Y. Li, Y. Xia, H. Xie, H. Zhong, M.T. Khan, J. Zhang, J. Li, L. Xiao, J. Al-Aama, D. Zhang, Y.S. Lee, D. Kotowska, C. Colding, V. Tremaroli, Y. Yin, S. Bergman, X. Xu, L. Madsen, K. Kristiansen, J. Dahlgren, J. Wang, W. Jun, Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17, 690–703 (2015). https://doi.org/10.1016/j.chom.2015.04.004
B.S. Ramakrishna, The normal bacterial flora of the human intestine and its regulation. J. Clin. Gastroenterol. 41, S2–S6 (2007)
F. Bäckhed, C.M. Fraser, Y. Ringel, M.E. Sanders, R.B. Sartor, P.M. Sherman, J. Versalovic, V. Young, B.B. Finlay, Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe 12, 611–622 (2012). https://doi.org/10.1016/j.chom.2012.10.012
Human Microbiome Project C., A framework for human microbiome research. Nature 486, 215–221 (2012). https://doi.org/10.1038/nature11209
E.A. Grice, J.A. Segre, The human microbiome: our second genome. Annu. Rev. Genom. Hum. Genet. 13, 151–170 (2012). https://doi.org/10.1146/annurev-genom-090711-163814
D.A. Hill, D. Artis, Intestinal bacteria and the regulation of immune cell homeostasis. Annu. Rev. Immunol. 28, 623–667 (2010). https://doi.org/10.1146/annurev-immunol-030409-101330
C. Mueller, A.J. Macpherson, Layers of mutualism with commensal bacteria protect us from intestinal inflammation. Gut 55, 276–284 (2006)
F. Guarner, J.-R. Malagelada, Gut flora in health and disease. Lancet 361, 512–519 (2003). https://doi.org/10.1016/S0140-6736(03)12489-0
I. Rowland, G. Gibson, A. Heinken, K. Scott, J. Swann, I. Thiele, K. Tuohy, Gut microbiota functions: metabolism of nutrients and other food components. Eur. J. Nutr. 57(1), 1–24 (2017). https://doi.org/10.1007/s00394-017-1445-8
L. Capurso, Il Microbiota intestinale. Recent. Prog. Med. 107, 257–266 (2016)
E.F. Enright, C.G.M. Gahan, S.A. Joyce, B.T. Griffin, The impact of the gut microbiota on drug metabolism and clinical outcome. Yale J. Biol. Med. 89, 375–382 (2016)
D.R. Donohoe, N. Garge, X. Zhang, W. Sun, T.M. O’Connell, M.K. Bunger, S.J. Bultman, The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 13, 517–526 (2011). https://doi.org/10.1016/j.cmet.2011.02.018
N. Kobyliak, O. Virchenko, T. Falalyeyeva, Pathophysiological role of host microbiota in the development of obesity. Nutr. J. 15, 1–12 (2016). https://doi.org/10.1186/s12937-016-0166-9
Y.E. Borre, G.W. O’Keeffe, G. Clarke, C. Stanton, T.G. Dinan, J.F. Cryan, Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol. Med. 20, 509–518 (2014). https://doi.org/10.1016/j.molmed.2014.05.002
D.J. Morrison, T. Preston, Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 7, 189–200 (2016). https://doi.org/10.1080/19490976.2015.1134082
G. den Besten, K. van Eunen, A.K. Groen, K. Venema, D.-J. Reijngoud, B.M. Bakker, The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325–2340 (2013). https://doi.org/10.1194/jlr.R036012
G.T. Macfarlane, G.R. Gibson, J.H. Cummings, Comparison of fermentation reactions in different regions of the human colon. J. Appl. Bacteriol. 72, 57–64 (1992). https://doi.org/10.1111/j.1365-2672.1992.tb04882.x
J.G. LeBlanc, F. Chain, R. Martín, L.G. Bermúdez-Humarán, S. Courau, P. Langella, Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. Microb. Cell Fact. 16, 1–10 (2017). https://doi.org/10.1186/s12934-017-0691-z
C.K. Chakraborti, New-found link between microbiota and obesity. World J. Gastrointest. Pathophysiol. 6, 110–119 (2015). https://doi.org/10.4291/wjgp.v6.i4.110
X. Li, Y. Shimizu, I. Kimura, Gut microbial metabolite short-chain fatty acids and obesity. Biosci. Micro., Food Heal. 36, 135–140 (2017). https://doi.org/10.12938/bmfh.17-010
P. Schönfeld, L. Wojtczak, Short- and medium-chain fatty acids in energy metabolism: the cellular perspective. J. Lipid Res. 57, 943–954 (2016). https://doi.org/10.1194/jlr.R067629
D.N. Cooper, R.J. Martin, N.L. Keim, Does whole grain consumption alter gut microbiota and satiety? Healthc. (Basel, Switz.) 3, 364–392 (2015). https://doi.org/10.3390/healthcare3020364
A. Everard, P.D. Cani, Gut microbiota and GLP-1. Rev. Endocr. Metab. Disord. 15, 189–196 (2014)
G. Frost, M.L. Sleeth, M. Sahuri-Arisoylu, B. Lizarbe, S. Cerdan, L. Brody, J. Anastasovska, S. Ghourab, M. Hankir, S. Zhang, D. Carling, J.R. Swann, G. Gibson, A. Viardot, D. Morrison, E.L. Thomas, J.D. Bell, The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat. Commun. 5, 3611 (2014). https://doi.org/10.1038/ncomms4611
L.E.M. Willemsen, M.A. Koetsier, S.J.H. van Deventer, E.A.F. van Tol, Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut 52, 1442–1447 (2003)
F.J. Cousin, S. Jouan-Lanhouet, N. Theret, C. Brenner, E. Jouan, G. Le Moigne-Muller, M.-T. Dimanche-Boitrel, G. Jan, The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer. Oncotarget 7, 7161–7178 (2016). https://doi.org/10.18632/oncotarget.6881
J. Ni, G.D. Wu, L. Albenberg, V.T. Tomov, Gut microbiota and IBD: Causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 14, 573–584 (2017)
H.J. Flint, E.A. Bayer, Plant cell wall breakdown by anaerobic microorganisms from the mammalian digestive tract. Ann. New Y. Acad. Sci. 1125, 280–288 (2008)
P. van den Abbeele, P. Gérard, S. Rabot, A. Bruneau, S. El Aidy, M. Derrien, M. Kleerebezem, E.G. Zoetendal, H. Smidt, W. Verstraete, T. van de Wiele, S. Possemiers, Arabinoxylans and inulin differentially modulate the mucosal and luminal gut microbiota and mucin-degradation in humanized rats. Environ. Microbiol. 13, 2667–2680 (2011). https://doi.org/10.1111/j.1462-2920.2011.02533.x
A.L. McOrist, R.B. Miller, A.R. Bird, J.B. Keogh, M. Noakes, D.L. Topping, M.A. Conlon, Fecal butyrate levels vary widely among individuals but are usually increased by a diet high in resistant starch. J. Nutr. 141, 883–889 (2011). https://doi.org/10.3945/jn.110.128504
C. Grootaert, P. Van Den Abbeele, M. Marzorati, W.F. Broekaert, C.M. Courtin, J.A. Delcour, W. Verstraete, T. Van De Wiele, Comparison of prebiotic effects of arabinoxylan oligosaccharides and inulin in a simulator of the human intestinal microbial ecosystem. FEMS Microbiol. Ecol. 69, 231–242 (2009). https://doi.org/10.1111/j.1574-6941.2009.00712.x
M. Begley, C. Hill, C.G.M. Gahan, Bile salt hydrolase activity in probiotics. Appl. Environ. Microbiol. 72, 1729–1738 (2006). https://doi.org/10.1128/AEM.72.3.1729-1738.2006
WHO | Obesity and overweight. (WHO, Geneva, Switzerland, 2018)
K. Ball, G. Mishra, D. Crawford, Which aspects of socioeconomic status are related to obesity among men and women? Int. J. Obes. Relat. Metab. Disord. 26, 559–565 (2002). https://doi.org/10.1038/sj.ijo.0801960
J.F. Rawls, M.A. Mahowald, R.E. Ley, J.I. Gordon, Reciprocal gut microbiota transplants from zebrafish and mice to germ-free recipients reveal host habitat selection. Cell 127, 423–433 (2018). https://doi.org/10.1016/j.cell.2006.08.043
R. Ley, P. Turnbaugh, S. Klein, J. Gordon, Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023 (2006). https://doi.org/10.1038/nature4441021a
M.A. Hildebrandt, C. Hoffman, S.A. Sherrill-Mix, S.A. Keilbaugh, M. Hamady, Y.-Y. Chen, R. Knight, R.S. Ahima, F. Bushman, G.D. Wu, High fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 137, 1712–1716 (2009). https://doi.org/10.1053/j.gastro.2009.08.042
P.J. Turnbaugh, F. Bäckhed, L. Fulton, J.I. Gordon, Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3, 213–223 (2008). https://doi.org/10.1016/j.chom.2008.02.015
M.A. Conlon, A.R. Bird, The impact of diet and lifestyle on gut microbiota and human health. Nutrients 7, 17–44 (2015). https://doi.org/10.3390/nu7010017
J. Hamzelou, Antibiotic overuse may promote obesity. New Sci. 213, 8–9 (2012). https://doi.org/10.1016/S0262-4079(12)60797-0
L. Trasande, J. Blustein, M. Liu, E. Corwin, L.M. Cox, M.J. Blaser, Infant antibiotic exposures and early-life body mass. Int. J. Obes. (Lond.). 37, 16–23 (2013). https://doi.org/10.1038/ijo.2012.132
L. Dethlefsen, D.A. Relman, Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. U.S.A. 108, Suppl, 4554–4561 (2011). https://doi.org/10.1073/pnas.1000087107
P. Vangay, T. Ward, J.S. Gerber, D. Knights, Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe 17, 553–564 (2015). https://doi.org/10.1016/J.CHOM.2015.04.006
F. Bäckhed, H. Ding, T. Wang, L.V. Hooper, G.Y. Koh, A. Nagy, C.F. Semenkovich, J.I. Gordon, The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. U.S.A. 101, 15718–15723 (2004). https://doi.org/10.1073/pnas.0407076101
P.J. Turnbaugh, R.E. Ley, M.A. Mahowald, V. Magrini, E.R. Mardis, J.I. Gordon, An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006). https://doi.org/10.1038/nature05414
A.P. Liou, M. Paziuk, J.M. Luevano, S. Machineni, P.J. Turnbaugh, L.M. Kaplan, Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci. Transl. Med. 5, 178ra41 (2013). https://doi.org/10.1126/scitranslmed.3005687
S. Kersten, S. Mandard, N.S. Tan, P. Escher, D. Metzger, P. Chambon, F.J. Gonzalez, B. Desvergne, W. Wahli, Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 275, 28488–28493 (2000). https://doi.org/10.1074/jbc.M004029200
E.M. Cushing, X. Chi, K.L. Sylvers, S.K. Shetty, M.J. Potthoff, B.S.J. Davies, Angiopoietin-like 4 directs uptake of dietary fat away from adipose during fasting. Mol. Metab. 6, 809–818 (2017). https://doi.org/10.1016/j.molmet.2017.06.007
F. Bäckhed, J.K. Manchester, C.F. Semenkovich, J.I. Gordon, Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl Acad. Sci. U.S.A. 104, 979–984 (2007). https://doi.org/10.1073/pnas.0605374104
N.E. Boutagy, R.P. McMillan, M.I. Frisard, M.W. Hulver, Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie 124, 11–20 (2016). https://doi.org/10.1016/j.biochi.2015.06.020
H. Ghanim, S. Abuaysheh, C.L. Sia, K. Korzeniewski, A. Chaudhuri, J.M. Fernandez-Real, P. Dandona, Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: Implications for insulin resistance. Diabetes Care 32, 2281–2287 (2009). https://doi.org/10.2337/dc09-0979
P.D. Cani, J. Amar, M.A. Iglesias, M. Poggi, C. Knauf, D. Bastelica, A.M. Neyrinck, F. Fava, K.M. Tuohy, C. Chabo, A. Waget, E. Delmée, B. Cousin, T. Sulpice, B. Chamontin, J. Ferrières, J.F. Tanti, G.R. Gibson, L. Casteilla, N.M. Delzenne, M.C. Alessi, R. Burcelin, Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772 (2007). https://doi.org/10.2337/db06-1491
M.M. Mihaylova, R.J. Shaw, The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell. Biol. 13, 1016–1023 (2011). https://doi.org/10.1038/ncb2329
E. Le Poul, C. Loison, S. Struyf, J.-Y. Springael, V. Lannoy, M.-E. Decobecq, S. Brezillon, V. Dupriez, G. Vassart, J. Van Damme, M. Parmentier, M. Detheux, Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 278, 25481–25489 (2003). https://doi.org/10.1074/jbc.M301403200
A.J. Brown, S.M. Goldsworthy, A.A. Barnes, M.M. Eilert, L. Tcheang, D. Daniels, A.I. Muir, M.J. Wigglesworth, I. Kinghorn, N.J. Fraser, N.B. Pike, J.C. Strum, K.M. Steplewski, P.R. Murdock, J.C. Holder, F.H. Marshall, P.G. Szekeres, S. Wilson, D.M. Ignar, S.M. Foord, A. Wise, S.J. Dowell, The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278, 11312–11319 (2003). https://doi.org/10.1074/jbc.M211609200
B.S. Samuel, A. Shaito, T. Motoike, F.E. Rey, F. Backhed, J.K. Manchester, R.E. Hammer, S.C. Williams, J. Crowley, M. Yanagisawa, J.I. Gordon, Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc. Natl Acad. Sci. 105, 16767–16772 (2008)
M. Bjursell, T. Admyre, M. Göransson, A.E. Marley, D.M. Smith, J. Oscarsson, M. Bohlooly-Y, Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am. J. Physiol. Metab. 300, E211–E220 (2010). https://doi.org/10.1152/ajpendo.00229.2010
V.K. Ridaura, J.J. Faith, F.E. Rey, J. Cheng, A.E. Duncan, A.L. Kau, N.W. Griffin, V. Lombard, B. Henrissat, J.R. Bain, M.J. Muehlbauer, O. Ilkayeva, C.F. Semenkovich, K. Funai, D.K. Hayashi, B.J. Lyle, M.C. Martini, L.K. Ursell, J.C. Clemente, W. Van Treuren, W.A. Walters, R. Knight, C.B. Newgard, A.C. Heath, J.I. Gordon, Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214 (2013). https://doi.org/10.1126/science.1241214
N.-R. Shin, J.-C. Lee, H.-Y. Lee, M.-S. Kim, T.W. Whon, M.-S. Lee, J.-W. Bae, An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63, 727–735 (2014). https://doi.org/10.1136/gutjnl-2012-303839
American Diabetes Association A.D., Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1), S62–S69 (2010). https://doi.org/10.2337/dc10-S062
WHO Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. (WHO, Geneva, Switzerland, 2013)
F. Navab-Moghadam, M. Sedighi, M.E. Khamseh, F. Alaei-Shahmiri, M. Talebi, S. Razavi, N. Amirmozafari, The association of type II diabetes with gut microbiota composition. Microb. Pathog. 110, 630–636 (2017). https://doi.org/10.1016/j.micpath.2017.07.034
H. Wu, E. Esteve, V. Tremaroli, M.T. Khan, R. Caesar, L. Mannerås-Holm, M. Ståhlman, L.M. Olsson, M. Serino, M. Planas-Fèlix, G. Xifra, J.M. Mercader, D. Torrents, R. Burcelin, W. Ricart, R. Perkins, J.M. Fernàndez-Real, F. Bäckhed, Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850–858 (2017). https://doi.org/10.1038/nm.4345
M.C. De Goffau, S. Fuentes, B. Van Den Bogert, H. Honkanen, W.M. De Vos, G.W. Welling, H. Hyöty, H.J.M. Harmsen, Aberrant gut microbiota composition at the onset of type 1 diabetes in young children. Diabetologia 57, 1569–1577 (2014). https://doi.org/10.1007/s00125-014-3274-0
S. Hasan, V. Aho, P. Pereira, L. Paulin, S.B. Koivusalo, P. Auvinen, J.G. Eriksson, Gut microbiome in gestational diabetes: a cross-sectional study of mothers and offspring 5 years postpartum. Acta Obstet. Gynecol. Scand. 97, 38–46 (2018). https://doi.org/10.1111/aogs.13252
N. Larsen, F.K. Vogensen, F.W.J. Van Den Berg, D.S. Nielsen, A.S. Andreasen, B.K. Pedersen, W.A. Al-Soud, S.J. Sørensen, L.H. Hansen, M. Jakobsen, Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 5, e9085 (2010). https://doi.org/10.1371/journal.pone.0009085
D. Ríos-Covián, P. Ruas-Madiedo, A. Margolles, M. Gueimonde, C.G. de Los Reyes-Gavilán, N. Salazar, Intestinal short chain fatty acids and their link with diet and human health. Front. Microbiol. 7, 185 (2016). https://doi.org/10.3389/fmicb.2016.00185
Z. Gao, J. Yin, J. Zhang, R.E. Ward, R.J. Martin, M. Lefevre, W.T. Cefalu, J. Ye, Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58, 1509–1517 (2009). https://doi.org/10.2337/db08-1637
H.V. Lin, A. Frassetto, E.J. Kowalik, A.R. Nawrocki, M.M. Lu, J.R. Kosinski, J.A. Hubert, D. Szeto, X. Yao, G. Forrest, D.J. Marsh, Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS ONE 7, e35240 (2012). https://doi.org/10.1371/journal.pone.0035240
R.J. Perry, L. Peng, N.A. Barry, G.W. Cline, D. Zhang, R.L. Cardone, K.F. Petersen, R.G. Kibbey, A.L. Goodman, G.I. Shulman, Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome. Nature 534, 213–217 (2016). https://doi.org/10.1038/nature18309
S. Devaraj, P. Hemarajata, J. Versalovic, The human gut microbiome and body metabolism: Implications for obesity and diabetes. Clin. Chem. 59, 617–628 (2013)
M.A.R. Vinolo, H.G. Rodrigues, R.T. Nachbar, R. Curi, Regulation of inflammation by short chain fatty acids. Nutrients 3, 858–876 (2011)
A. Vrieze, E. Van Nood, F. Holleman, J. Salojärvi, R.S. Kootte, J.F.W.M. Bartelsman, G.M. Dallinga-Thie, M.T. Ackermans, M.J. Serlie, R. Oozeer, M. Derrien, A. Druesne, J.E.T. Van Hylckama Vlieg, V.W. Bloks, A.K. Groen, H.G.H.J. Heilig, E.G. Zoetendal, E.S. Stroes, W.M. De Vos, J.B.L. Hoekstra, M. Nieuwdorp, Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143, 913–6.e7 (2012). https://doi.org/10.1053/j.gastro.2012.06.031
P.D. Cani, N.M. Delzenne, The role of the gut microbiota in energy metabolism and metabolic disease. Curr. Pharm. Des. 15, 1546–1558 (2009). https://doi.org/10.2174/138161209788168164
P.D. Cani, S. Possemiers, T. Van De Wiele, Y. Guiot, A. Everard, O. Rottier, L. Geurts, D. Naslain, A. Neyrinck, D.M. Lambert, G.G. Muccioli, N.M. Delzenne, Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091–1103 (2009). https://doi.org/10.1136/gut.2008.165886
S. Hædersdal, A. Lund, F.K. Knop, T. Vilsbøll, The role of glucagon in the pathophysiology and treatment of type 2 diabetes. Mayo Clin. Proc. 93, 217–239 (2018). https://doi.org/10.1016/j.mayocp.2017.12.003
C.S. Marathe, C.K. Rayner, K.L. Jones, M. Horowitz, Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care. 36, 1396–1405 (2013). https://doi.org/10.2337/dc12-1609
G.S. Papaetis, Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J. Diabetes 5, 817–834 (2014). https://doi.org/10.4239/wjd.v5.i6.817
J. Bland, Intestinal microbiome, akkermansia muciniphila, and medical nutrition therapy. Integr. Med. (Encinitas). 15, 14–16 (2016). https://doi.org/10.1136/gutjnl-2015-310904
K. Forslund, F. Hildebrand, T. Nielsen, G. Falony, E. Le Chatelier, S. Sunagawa, E. Prifti, S. Vieira-Silva, V. Gudmundsdottir, H. Krogh Pedersen, M. Arumugam, K. Kristiansen, A. Yvonne Voigt, H. Vestergaard, R. Hercog, P. Igor Costea, J. Roat Kultima, J. Li, T. Jørgensen, F. Levenez, J. Dore, H. Bjørn Nielsen, S. Brunak, J. Raes, T. Hansen, J. Wang, S. Dusko Ehrlich, P. Bork, O. Pedersen, Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262–266 (2015). https://doi.org/10.1038/nature15766
N.M. Maruthur, E. Tseng, S. Hutfless, L.M. Wilson, C. Suarez-Cuervo, Z. Berger, Y. Chu, E. Iyoha, J.B. Segal, S. Bolen, Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. Ann. Intern. Med. 164, 740–751 (2016)
D. Kopelman, I. Caterson, J. Michael, W. HD, Clinical obesity in adults and children. (2009)
K.M. Levri, E. Slaymaker, A. Last, J. Yeh, J. Ference, F. D’Amico, S.A. Wilson, Metformin as treatment for overweight and obese adults: A systematic review. Ann. Fam. Med. 3, 457–461 (2005)
M.P. van der Aa, M.A.J. Elst, E.M.W. van de Garde, E.G.A.H. van Mil, C.A.J. Knibbe, M.M.J. van der Vorst, Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr. Diabetes 6, e228 (2016). https://doi.org/10.1038/nutd.2016.37
U. Uusitalo, X. Liu, J. Yang, C.A. Aronsson, S. Hummel, M. Butterworth, Å. Lernmark, M. Rewers, W. Hagopian, J.-X. She, O. Simell, J. Toppari, A.G. Ziegler, B. Akolkar, J. Krischer, J.M. Norris, S.M. Virtanen; TEDDY Study Group, Association of early exposure of probiotics and islet autoimmunity in the TEDDY study. JAMA Pediatr. 33612, 1–9 (2015). https://doi.org/10.1001/jamapediatrics.2015.2757
W.-H. Lee, P.-C. Hsu, C.-Y. Chu, H.-M. Su, C.-S. Lee, H.-W. Yen, T.-H. Lin, W.-C. Voon, W.-T. Lai, S.-H. Sheu, Cardiovascular events in patients with atherothrombotic disease: a population-based longitudinal study in Taiwan. PLoS. One. 9, e92577 (2014). https://doi.org/10.1371/journal.pone.0092577
C. Gazzaruso, S.B. Solerte, E. De Amici, M. Mancini, A. Pujia, P. Fratino, A. Giustina, A. Garzaniti, Association of the metabolic syndrome and insulin resistance with silent myocardial ischemia in patients with type 2 diabetes mellitus. Am. J. Cardiol. 97, 236–239 (2006). https://doi.org/10.1016/j.amjcard.2005.07.133
C. Gazzaruso, A. Coppola, A. Giustina, Erectile dysfunction and coronary artery disease in patients with diabetes. Curr. Diabetes Rev. 7, 143–147 (2011). https://doi.org/10.2174/157339911794940693
G.S. Crowther, M.H. Wilcox, Antibiotic therapy and Clostridium difficile infection -primum non nocere - first do no harm. Infect. Drug Resist. 8, 333–337 (2015). https://doi.org/10.2147/IDR.S87224
W.H.W. Tang, Z. Wang, D.J. Kennedy, Y. Wu, J.A. Buffa, B. Agatisa-Boyle, X.S. Li, B.S. Levison, S.L. Hazen, Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 116, 448–455 (2015). https://doi.org/10.1161/CIRCRESAHA.116.305360
R.A. Koeth, Z. Wang, B.S. Levison, J.A. Buffa, E. Org, B.T. Sheehy, E.B. Britt, X. Fu, Y. Wu, L. Li, J.D. Smith, J.A. Didonato, J. Chen, H. Li, G.D. Wu, J.D. Lewis, M. Warrier, J.M. Brown, R.M. Krauss, W.H.W. Tang, F.D. Bushman, A.J. Lusis, S.L. Hazen, Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576–585 (2013). https://doi.org/10.1038/nm.3145
R.A. Koeth, B.S. Levison, M.K. Culley, J.A. Buffa, Z. Wang, J.C. Gregory, E. Org, Y. Wu, L. Li, J.D. Smith, W.H.W. Tang, J.A. Didonato, A.J. Lusis, S.L. Hazen, γ-butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell. Metab. 20, 799–812 (2014). https://doi.org/10.1016/j.cmet.2014.10.006
W.H.W. Tang, Z. Wang, Y. Fan, B. Levison, J.E. Hazen, L.M. Donahue, Y. Wu, S.L. Hazen, Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: Refining the gut hypothesis. J. Am. Coll. Cardiol. 64, 1908–1914 (2014)
W.P. Fay, Homocysteine and thrombosis: Guilt by association? Blood 119, 2977–2978 (2012)
R. Ostan, M.C. Béné, L. Spazzafumo, A. Pinto, L.M. Donini, F. Pryen, Z. Charrouf, L. Valentini, H. Lochs, I. Bourdel-Marchasson, C. Blanc-Bisson, F. Buccolini, P. Brigidi, C. Franceschi, P.A. d’Alessio, Impact of diet and nutraceutical supplementation on inflammation in elderly people. Results from the RISTOMED study, an open-label randomized control trial. Clin. Nutr. 35, 812–818 (2016). https://doi.org/10.1016/j.clnu.2015.06.010
J.L. Griffin, X. Wang, E. Stanley, Does Our gut microbiome predict cardiovascular risk? A review of the evidence from metabolomics. Circ. Cardiovasc Genet. 8, 187–191 (2015)
J. Joseph, J. Loscalzo, Nutri(meta)genetics and cardiovascular disease: novel concepts in the interaction of diet and genomic variation. Curr. Atherosler Rep. 17, 505 (2015)
W.H.W. Tang, S.L. Hazen, The contributory role of gut microbiota in cardiovascular disease. J. Clin. Invest. 124, 4204–4211 (2014). https://doi.org/10.1172/JCI72331
T. Yang, M.M. Santisteban, V. Rodriguez, E. Li, N. Ahmari, J.M. Carvajal, M. Zadeh, M. Gong, Y. Qi, J. Zubcevic, B. Sahay, C.J. Pepine, M.K. Raizada, M. Mohamadzadeh, Gut dysbiosis is linked to hypertension. Hypertension 65, 1331–1340 (2015). https://doi.org/10.1161/HYPERTENSIONAHA.115.05315
X.T. Gan, G. Ettinger, C.X. Huang, J.P. Burton, J.V. Haist, V. Rajapurohitam, J.E. Sidaway, G. Martin, G.B. Gloor, J.R. Swann, G. Reid, M. Karmazyn, Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ. Hear. Fail. 7, 491–499 (2014). https://doi.org/10.1161/CIRCHEARTFAILURE.113.000978
C.S. Hampe, C.L. Roth, Probiotic strains and mechanistic insights for the treatment of type 2 diabetes. Endocrine 58, 207–227 (2017). https://doi.org/10.1007/s12020-017-1433-z
M.H. Floch, Probiotics and prebiotics. Gastroenterol. Hepatol. (N. Y) 10, 680–681 (2014)
M.C. Dao, A. Everard, J. Aron-Wisnewsky, N. Sokolovska, E. Prifti, E.O. Verger, B.D. Kayser, F. Levenez, J. Chilloux, L. Hoyles, M.-E. Dumas, S.W. Rizkalla, J. Doré, P.D. Cani, K. Clément, Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65, 426–436 (2016)
C. Chevalier, O. Stojanović, D.J. Colin, N. Suarez-Zamorano, V. Tarallo, C. Veyrat-Durebex, D. Rigo, S. Fabbiano, A. Stevanović, S. Hagemann, X. Montet, Y. Seimbille, N. Zamboni, S. Hapfelmeier, M. Trajkovski, Gut microbiota orchestrates energy homeostasis during cold. Cell 163, 1360–1374 (2015). https://doi.org/10.1016/j.cell.2015.11.004
L.J. Cohen, D. Esterhazy, S.-H. Kim, C. Lemetre, R.R. Aguilar, E.A. Gordon, A.J. Pickard, J.R. Cross, A.B. Emiliano, S.M. Han, J. Chu, X. Vila-Farres, J. Kaplitt, A. Rogoz, P.Y. Calle, C. Hunter, J.K. Bitok, S.F. Brady, Commensal bacteria make GPCR ligands that mimic human signalling molecules. Nature 549, 48–53 (2017). https://doi.org/10.1038/nature23874
M. Mimee, R.J. Citorik, T.K. Lu, Microbiome therapeutics—Advances and challenges. Adv. Drug. Deliv. Rev. 105, 44–54 (2016)
Z.Z.R. Hamady, N. Scott, M.D. Farrar, M. Wadhwa, P. Dilger, T.R. Whitehead, R. Thorpe, K.T. Holland, J.P.A. Lodge, S.R. Carding, Treatment of colitis with a commensal gut bacterium engineered to secrete human tgf-β1 under the control of dietary xylan 1. Inflamm. Bowel. Dis. 17, 1925–1935 (2011). https://doi.org/10.1002/ibd.21565
K. Vandenbroucke, H. De Haard, E. Beirnaert, T. Dreier, M. Lauwereys, L. Huyck, J. Van Huysse, P. Demetter, L. Steidler, E. Remaut, C. Cuvelier, P. Rottiers, Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 3, 49–56 (2010). https://doi.org/10.1038/mi.2009.116
Z.Z.R. Hamady, N. Scott, M.D. Farrar, J.P.A. Lodge, K.T. Holland, T. Whitehead, S.R. Carding, Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut 59, 461–469 (2010)
J.P. Motta, L.G. Bermúdez-Humarán, C. Deraison, L. Martin, C. Rolland, P. Rousset, J. Boue, G. Dietrich, K. Chapman, P. Kharrat, J.P. Vinel, L. Alric, E. Mas, J.M. Sallenave, P. Langella, N. Vergnolle, Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci. Transl. Med. 4, 158ra144 (2012). https://doi.org/10.1126/scitranslmed.3004212
G.R. Gibson, H.M. Probert, J.Van Loo, R.A. Rastall, M.B. Roberfroid, Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr. Res. Rev. 17, 259 (2004). https://doi.org/10.1079/NRR200479
J. Slavin, Fiber and prebiotics: mechanisms and health benefits. Nutrients 5, 1417–1435 (2013). https://doi.org/10.3390/nu5041417
M. De Vrese, J. Schrezenmeir, Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 111, 1–66 (2008)
B.C. Tungland, D. Meyer, Nondigestible oligo- and polysaccharides (dietary fiber): Their physiology and role in human health and food. Compr. Rev. Food Sci. Food Saf. 1, 90–109 (2002). https://doi.org/10.1111/j.1541-4337.2002.tb00009.x
Z. Wang, E. Klipfell, B.J. Bennett, R. Koeth, B.S. Levison, B. Dugar, A.E. Feldstein, E.B. Britt, X. Fu, Y.M. Chung, Y. Wu, P. Schauer, J.D. Smith, H. Allayee, W.H.W. Tang, J.A. Didonato, A.J. Lusis, S.L. Hazen, Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–65 (2011). https://doi.org/10.1038/nature09922
A. Coppola, L. Sasso, A. Bagnasco, A. Giustina, C. Gazzaruso, The role of patient education in the prevention and management of type 2 diabetes: an overview. Endocrine 53, 18–27 (2016)
V. Tosti, B. Bertozzi, L. Fontana, Health Benefits of the Mediterranean Diet: Metabolic and Molecular Mechanisms. J Gerontol A Biol Sci Med Sci. 73, 318–326 (2018)
T.T.B. Nguyen, Y.Y. Jin, H.J. Chung, S.T. Hong, Pharmabiotics as an emerging medication for metabolic syndrome and its related diseases. Molecules 22(10), E1795 (2017)
R.E. Ley, D.A. Peterson, J.I. Gordon, Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124, 837–848 (2006). https://doi.org/10.1016/J.CELL.2006.02.017
R.E. Ley, F. Bäckhed, P. Turnbaugh, C.A. Lozupone, R.D. Knight, J.I. Gordon, Obesity alters gut microbial ecology. Proc. Natl Acad. Sci. U. S. A. 102, 11070–11075 (2005). https://doi.org/10.1073/pnas.0504978102
A.L. Komaroff, The microbiome and risk for obesity and diabetes. JAMA 317, 355 (2017). https://doi.org/10.1001/jama.2016.20099
S.K. Mazmanian, J.L. Round, D.L. Kasper, A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453, 620–625 (2008). https://doi.org/10.1038/nature07008
L. Wen, R.E. Ley, P.Y. Volchkov, P.B. Stranges, L. Avanesyan, A.C. Stonebraker, C. Hu, F.S. Wong, G.L. Szot, J.A. Bluestone, J.I. Gordon, A.V. Chervonsky, Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455, 1109–1113 (2008). https://doi.org/10.1038/nature07336
Y.S. Kim, J.A. Milner, Dietary modulation of colon cancer risk. J. Nutr. 137, 2576S–2579S (2007)
S.K.P. Lau, P.C.Y. Woo, G.K.S. Woo, A.M.Y. Fung, M.K.M. Wong, K.-M. Chan, D.M.W. Tam, K.-Y. Yuen, Eggerthella hongkongensis sp. nov. and eggerthella sinensis sp. nov., two novel Eggerthella species, account for half of the cases of Eggerthella bacteremia. Diagn. Microbiol. Infect. Dis. 49, 255–263 (2004). https://doi.org/10.1016/j.diagmicrobio.2004.04.012
M. Kraatz, R.J. Wallace, L. Svensson, Olsenella umbonata sp. nov., a microaerotolerant anaerobic lactic acid bacterium from the sheep rumen and pig jejunum, and emended descriptions of Olsenella, Olsenella uli and Olsenella profusa. Int. J. Syst. Evol. Microbiol. 61, 795–803 (2011). https://doi.org/10.1099/ijs.0.022954-0
S.K. Lau, P.C. Woo, A.M. Fung, K. Chan, G.K. Woo, K. Yuen, Anaerobic, non-sporulating, Gram-positive bacilli bacteraemia characterized by 16S rRNA gene sequencing. J. Med. Microbiol. 53, 1247–1253 (2004). https://doi.org/10.1099/jmm.0.45803-0
A. Finamore, M. Palmery, S. Bensehaila, I. Peluso, Antioxidant, immunomodulating, and microbial-modulating activities of the sustainable and ecofriendly Spirulina. Oxid. Med. Cell Longev. 2017, 3247528 (2017). https://doi.org/10.1155/2017/3247528. 1–14
D.J. Hampson, T. La, N.D. Phillips, Emergence of Brachyspira species and strains: reinforcing the need for surveillance. Porc. Heal. Manag. 1, 8 (2015). https://doi.org/10.1186/s40813-015-0002-1
M.Y. Galperin, New feel for new phyla. Environ. Microbiol. 10, 1927–1933 (2008). https://doi.org/10.1111/j.1462-2920.2008.01699.x
M. Yamauchi, P. Lochhead, T. Morikawa, C. Huttenhower, A.T. Chan, E. Giovannucci, C. Fuchs, S. Ogino, Colorectal cancer: a tale of two sides or a continuum? Gut 61, 794–797 (2012). https://doi.org/10.1136/gutjnl-2012-302014
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
The present editorial complies with ethical requirements.
Rights and permissions
About this article
Cite this article
Pascale, A., Marchesi, N., Marelli, C. et al. Microbiota and metabolic diseases. Endocrine 61, 357–371 (2018). https://doi.org/10.1007/s12020-018-1605-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-018-1605-5